Sanara Medtech Inc (SMTI)
Sanara MedTech Inc. is a Fort Worth, Texas-based medical technology company focused on developing, marketing, and distributing surgical solutions in the United States. Its products are used by physicians, hospitals, clinics, and post-acute care settings, with offerings that include CellerateRX Surgical for the management of surgical, traumatic, and burn wounds, as well as BIASURGE, a no-rinse surgical solution for wound irrigation. The company’s portfolio also includes regenerative and wound care products such as FORTIFY Tissue Repair Graft, BiFORM, ACTIGEN Inductive Bone Matrix, ALLOCYTE Plus, and TEXAGEN. In addition, Sanara MedTech has a license agreement with Rochal covering antimicrobial products including BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser. The company was incorporated in 2001 and its common stock is listed on NASDAQ under the ticker SMTI.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SMTI
|
$23.14
|
-9.0% Downside
|
Fair
|
$34.33
|
35.0% Upside
|
Undervalued
|
Great
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
366.0x
|
32.8x
|
2.1x
|
229.1 M
|
251.4 M
|
17.4%
|
40.8%
|
3.5
|
—
|
534.8%
|
